Newsroom
Category
June 18, 2021
Users reported relief in 92% of cases. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 18, 2021) — Researchers from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and colleagues worldwide describe a new science-based intervention for hiccups in a research letter published June 18 in the journal JAMA […]
June 17, 2021
(Editor’s note: This story, originally posted on Feb. 11, 2021, has been updated to include the study’s publication in JAMA Oncology on June 17, 2021.) Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 17, 2021) — Convalescent plasma therapy was associated with better survival in blood cancer patients hospitalized with COVID-19, especially in sicker patients. […]
June 17, 2021
Framingham Heart Study analysis finds association in APOE ε4 allele carriers. Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (June 17, 2021) — Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain’s emotion- and memory-controlling regions, a new […]
June 14, 2021
Contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu Elizabeth Allen, 210-358-2344, elizabeth.allen@uhs-sa.com SAN ANTONIO (June 14, 2021) — Researchers at UT Health San Antonio are buoyed by today’s news that the Novavax vaccine is strongly effective against the COVID-19 virus. Biotechnology company Novavax released Phase 3 clinical trial results from 119 sites in the U.S. and Mexico this […]
June 10, 2021
Editor’s note: This story, originally posted on June 10, 2020, is being reposted to include a link to this anonymous survey: http://bit.ly/BOOST3CommunitySurvey. The public comment phase leading up to the study is nearly complete, and feedback is welcomed. SAN ANTONIO (June 10, 2021) – A study of emergency care involving victims of severe brain […]
June 9, 2021
The U.S. Food and Drug Administration (FDA) on Monday, June 7, approved the drug aducanumab for the treatment of Alzheimer’s disease, which affects 6.2 million Americans. Sudha Seshadri, MD, professor of neurology at UT Health San Antonio and director of the university’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases, issued the following statement: “We are excited that a drug, aducanumab (Aduhelm, from Biogen), has been approved by the FDA for treatment of persons with early symptoms due to Alzheimer’s disease. This is the first new drug approved for Alzheimer’s in two decades.”
